Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Superselective intra-arterial cisplatin with radiotherapy for locally advanced oropharyngeal cancer
jRCTs011230065Phase 2Recruiting
- Sponsor
- Hokkaido University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in oropharyngeal cancer, sponsored by Hokkaido University Hospital. Primary endpoints: Dose-limiting toxicity rate and 2-year local event-free survival rate. Started Sep 2024; status: recruiting.
02
Drugs
cisplatin
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on jRCTs011230065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011230065.